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Introduction {#sec005}
============

Neoadjuvant chemotherapy (NCT) is now commonly considered for breast cancer patients who are potential candidates for adjuvant chemotherapy and it has been reported to have similar oncologic outcomes to adjuvant chemotherapy \[[@pone.0149347.ref001]\]. In addition, NCT increases the chances of successful breast-conservation surgery, facilitates tumor biology research, and most importantly, provides information about prognosis \[[@pone.0149347.ref001]--[@pone.0149347.ref003]\]. For these advantages to be of use in real clinical practice, accurate evaluation of response during NCT and preoperative assessment of residual tumor burden through imaging modalities are critical for planning the extent of surgery and for predicting prognosis. Recently, a meta-analysis suggested that breast magnetic resonance imaging (MRI) showed good performance in predicting pathologic complete response (pCR) after NCT \[[@pone.0149347.ref004]\].

Residual ductal carcinoma *in situ* (DCIS) components of breast cancer after NCT are considered as pCR; however, surgery is differently planned if these components are of no residual invasive and *in situ* carcinoma (ypT0). Obtaining clear resection margins with accurate preoperative evaluation helps decrease operation time and reduces the chances of repeating surgery or early local recurrence. Chen et al. \[[@pone.0149347.ref005]\] demonstrated that positive cavity margin was the only independent predictor for local-regional failure in patients treated with NCT before breast-conservation surgery according to univariate and multivariate analysis. Most clinicians usually plan the extent of surgery to achieve negative resections based on radiological examinations and clinicopathological parameters. However, it has not been established which parameters should have higher priority in daily practice.

In our review of previous literatures, there was only one article that dealt with discriminating ypT0 from residual DCIS in the breast after NCT \[[@pone.0149347.ref006]\]. In that study, the dynamic contrast-enhanced MRI was reported to show good performance for distinguishing between lesions with or without residual DCIS in breast cancer patients who demonstrated no residual invasive cancer after NCT \[[@pone.0149347.ref006]\]. However, the study sample was limited, including only 15 cases of residual *in situ* carcinoma. It is therefore difficult to generalize their results to other samples, or to analyze clinicopathological factors such as breast cancer phenotype, Ki-67 levels, or the use of human epidermal growth factor receptor-2 (HER2) targeted therapy \[[@pone.0149347.ref007],[@pone.0149347.ref008]\]. Thus, more comprehensive studies are necessary to determine the potential of MRI alongside future analyses of clinicopathological findings of breast cancer patients who receive NCT.

The aim of this study was to investigate independent clinicopathological and radiological characteristics, including breast cancer subtypes, in order to discriminate between ypT0 and residual DCIS alone (ypTis) on final pathology in breast cancer patients who responded well to NCT.

Patients and Methods {#sec006}
====================

Patient selection {#sec007}
-----------------

A total of 163 patients who achieved pCR in the breast after receiving NCT and who subsequently underwent definitive surgery of the breast and axilla from January 2010 to December 2013 at the Severance Hospital of Yonsei University College of Medicine, Seoul, Republic of Korea were retrospectively selected. All patients in the study cohort were histologically confirmed to have primary invasive breast carcinoma at initial presentation. After therapeutic surgery, permanent pathologic findings of the breast for all patients were reported as no residual invasive and *in situ* carcinoma (ypT0) or residual *in situ* carcinoma alone (ypTis), irrespective of pathologic nodal stage (ypNany). Forty-six (28.2%) patients who did not undergo mammography, ultrasound, and breast MRI both prior to and after NCT were excluded from analysis. Therefore, 117 patients were finally included in our study.

NCT regimens were mainly composed of 4 cycles of anthracycline plus cyclophosphamide (AC) followed by 4 cycles of docetaxel (T) every 3 weeks in 91 (77.8%) patients. Twelve (10.3%) patients received AC followed by T plus TS-1. Of the remaining 14 (12.0%) patients, 8 were treated with 6 cycles of T plus carboplatinum with bevacizumab and 2 received paclitaxel plus carboplatinum. Each patient went through one of four regimens: four cycles of AC, 6 cycles of TAC, T plus carboplatinum with trastzumab, or paclitaxel plus trastzumab. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea (IRB No. 4-2015-0247). The requirement for written informed consent was waived and patient information was anonymized and de-identified prior to analysis.

Clinicopathological characteristics {#sec008}
-----------------------------------

Clinicopathological information, including expression of the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67, was obtained through reviews of medical records and pathology reports. Tumors with ≥1% nuclear-stained cells by immunohistochemistry of core needle biopsy specimens prior to NCT were considered positive for hormone receptors (HRs) according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines \[[@pone.0149347.ref009]\]. HER2 staining was scored as 0, 1+, 2+, or 3+ according to ASCO/CAP guidelines \[[@pone.0149347.ref010]\]. In cases with HER2 2+ results, fluorescence *in situ* hybridization (FISH) was performed using a PathVysion *HER2* DNA Probe Kit (Vysis, Downers Grove, IL, USA) and HER2 gene amplification was defined with a HER2 gene/chromosome 17 copy number ratio ≥2.0 according to ASCO/CAP guidelines \[[@pone.0149347.ref010]\]. HER2 was considered positive with immunohistochemistry scores of 3+ or gene amplification by FISH. Ki-67 levels were scored by counting the number of positively stained nuclei and were expressed as a percentage of total tumor cells.

Breast cancer subtypes were categorized by HRs and HER2 expression as follows: HRs+/HER2-, ER-positive or PR-positive, and HER2-negative; HRs+/HER2+, ER-positive or PR-positive, and HER2-positive; HRs-/HER2+, ER-negative, PR-negative, and HER2-positive; HRs-/HER2-, ER-negative, PR-negative, and HER2-negative, a subtype also known as triple-negative breast cancer.

Interpretation and analysis of imaging study {#sec009}
--------------------------------------------

A radiologist (MJK) with more than 10 years of experience specializing in breast imaging interpreted mammography, ultrasound, and MRI images before and after NCT while blinded to clinicopathological information. Data on mammographic factors were collected by reviewing mammography before and after NCT and the mammographic factors reviewed were as follows. For mammography before NCT, tumor size (the largest diameter on mammography), the extent of the tumor \[single and multiple: the presence of two of more tumor foci within a single quadrant of the breast (multifocal) or within different quadrants of the same breast (multicentric)\], the presentation pattern of the main lesion (mass alone, the presence of microcalcifications regardless of mass, and non-visualization on mammography), the presence of associated microcalcifications for the main lesion, and other imaging characteristics of the main lesion (shape, margin, and density) and breast parenchymal patterns classified with the Breast Imaging Reporting and Data System (BI-RADS) by the American College of Radiology were studied \[[@pone.0149347.ref011]\]. For mammography after NCT, the mammographic factors studied for the presentation of the main lesion were as follows; complete response including cases undetected on mammography before NCT and residual mass or microcalcifications.

Ultrasonographic factors were reviewed and categorized as follows: For ultrasound before NCT, the tumor size was defined as the largest diameter on ultrasound and imaging findings of the main lesion were classified with BI-RADS \[[@pone.0149347.ref011]\]. Complete response or residual disease after NCT was also determined for ultrasound.

MRIs were reviewed before and after NCT and tumor size was defined as the largest diameter on the second post-contrast subtracted image. Background parenchymal enhancement was categorized into one of four levels (1. minimal, 2. mild, 3. moderate, and 4. marked). The type of lesion presented, the shape of the main lesion, the margin, the internal enhancement pattern, and the time-intensity curve (washout, plateau, and persistent) were assessed \[[@pone.0149347.ref011]\]. The time-intensity curve was evaluated using an automated software program (CADstream, Merge Healthcare, Chicago, IL, USA). The presence of intratumoral necrosis, fibrosis, perilesional edema, and the signal intensity of the lesion were evaluated with T2-weighted images (T2WI). Residual tumors were assessed on MRI after NCT. An enhancing area distinct from the background parenchymal enhancement was considered to indicate the presence of residual tumors. The absence of a distinct enhancing area was considered to indicate complete response to chemotherapy.

Statistical analyses {#sec010}
--------------------

Differences between the groups according to clinicopathological parameters were evaluated using the chi-square test. Fisher's exact test was used when appropriate. The independent two sample *t*-test was used to compare the means of continuous numerical data. The predictive value of imaging modality for the detection of residual DCIS at the time before surgery was analyzed by receiver operating characteristic (ROC) curve analysis with calculated area under the ROC curve (AUC). A logistic regression analysis was used to investigate independent parameters including breast cancer subtype associated with ypT0 after completion of NCT. The Cochran-Mantel-Haenszel test was used in stratified analyses according to breast cancer subtype to explore the relationships between MRI findings after NCT and ypT0. All statistical tests were two-sided, and *p*-values \<0.05 were considered statistically significant. The SPSS software version 20.0 (IBM Inc., Armonk, NY, USA) was used for all analyses.

Results {#sec011}
=======

Of 117 patients, 67 (57.3%) were ypT0 and 50 (42.7%) were ypTis after breast surgery. Mean age at diagnosis was 49.4 ± 9.7 years for the entire study sample. [Table 1](#pone.0149347.t001){ref-type="table"} presents clinicopathological characteristics according to presence of residual disease. There were no differences in clinical features, tumor burden at presentation, pathologic nodal status after NCT, histologic grade, Ki-67 proliferative index at diagnosis, or regimens of NCT between the two groups. Patients with ypT0 were more likely to have ER-negative, PR-negative, and HER2-negative tumors. Therefore, triple-negative breast cancer was significantly more common in the ypT0 group. Breast-conservation surgeries were more frequently performed in patients with ypT0.

10.1371/journal.pone.0149347.t001

###### Clinicopathological findings of patients with ypT0 and ypTis in the breast after neoadjuvant chemotherapy.

![](pone.0149347.t001){#pone.0149347.t001g}

  Parameters                             ypT0 (n = 67, %)   ypTis (n = 50, %)   *P*-value
  -------------------------------------- ------------------ ------------------- ---------------------------------------------
  Age (year)                                                                    
    Mean ± SD                            49.6 ± 10.4        49.1 ± 8.7          0.772[^a^](#t001fn002){ref-type="table-fn"}
    ≤40                                  13 (68.4)          6 (31.6)            0.283
    \>40                                 54 (55.1)          44 (44.9)           
  Menopause                                                                     
    Premenopause                         35 (56.5)          27 (43.5)           0.850
    Postmenopause                        32 (58.2)          23 (41.8)           
  BMI (kg/m^2^)                                                                 
    \<25                                 46 (57.5)          34 (42.5)           0.940
    ≥25                                  21 (56.8)          16 (43.2)           
  Clinical tumor stage at presentation                                          
    T1                                   26 (66.7)          13 (33.3)           0.340
    T2                                   34 (53.1)          30 (46.9)           
    T3-4                                 7 (50.0)           7 (50.0)            
  Node status at presentation                                                   
    Negative                             9 (64.3)           5 (35.7)            0.571
    Positive                             58 (56.3)          45 (43.7)           
  Regimens of NCT                                                               
    AC followed by T                     49 (73.1)          42 (84.0)           0.070
    AC followed by T+TS1                 6 (9.0)            6 (12.0)            
    Others                               12 (17.9)          2 (4.0)             
  Pathologic node status after NCT                                              
    ypN0                                 58 (60.4)          38 (39.6)           0.141
    ypN1-3                               9 (42.9)           12 (57.1)           
  Histologic grade                                                              
    I/II                                 36 (56.2)          28 (43.8)           0.807
    III                                  31 (58.5)          22 (41.5)           
  ER                                                                            
    Negative                             43 (65.2)          23 (34.8)           0.050
    Positive                             24 (47.1)          27 (52.9)           
  PR                                                                            
    Negative                             56 (62.2)          34 (37.8)           0.048
    Positive                             11 (40.7)          16 (59.3)           
  HER2                                                                          
    Negative                             50 (68.5)          23 (31.5)           0.002
    Positive                             17 (38.6)          27 (61.4)           
  Breast cancer subtype                                                         
    HRs+/HER2-                           17 (51.5)          16 (48.5)           0.001
    HRs+/HER2+                           7 (36.8)           12 (63.2)           
    HRs-/HER2+                           10 (40.0)          15 (60.0)           
    HRs-/HER2-                           33 (82.5)          7 (17.5)            
  Ki-67 before NCT (n = 105)                                                    
    ≤15%                                 17 (45.9)          20 (54.1)           0.119
    \>15%                                42 (61.8)          26 (38.2)           
  Surgery                                                                       
    Breast-conservation                  46 (68.7)          21 (31.3)           0.004
    Total mastectomy                     21 (42.0)          29 (58.0)           

SD, standard deviation; BMI, body mass index; NCT, neoadjuvant chemotherapy; AC, anthracycline plus cyclophosphamide; T, docetaxel; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HRs, hormone receptors.

^a^Independent samples *t*-test.

Mammographic findings for patients with ypT0 and ypTis are compared in [Table 2](#pone.0149347.t002){ref-type="table"} and [S1 Appendix](#pone.0149347.s001){ref-type="supplementary-material"}. At initial presentation, the size, extent, shape, and margin of the main lesion, mammographic parenchymal pattern, and density did not differ between patients with ypT0 and ypTis. The baseline main tumor frequently presented as microcalcifications with or without mass in the ypTis group. Associated microcalcifications were more frequent in patients with ypTis. After completion of NCT, mammographic findings of patients with ypT0 were significantly noted as either complete response or undetected.

10.1371/journal.pone.0149347.t002

###### Mammographic findings of patients with ypT0 and ypTis.

![](pone.0149347.t002){#pone.0149347.t002g}

  Parameters                                ypT0 (%)      ypTis (%)     *P*-value
  ----------------------------------------- ------------- ------------- ---------------------------------------------
  Before NCT                                                            
    Mean Size ± SD                          29.4 ± 21.8   33.7 ± 21.0   0.287[^a^](#t002fn001){ref-type="table-fn"}
    Extent                                                              
      Single                                46 (63.0)     27 (37.0)     0.105
      Multiple                              21 (47.7)     23 (52.3)     
    Parenchymal pattern                                                 
      b                                     19 (65.5)     10 (34.5)     0.078[^b^](#t002fn002){ref-type="table-fn"}
      c                                     41 (51.2)     39 (48.8)     
      d                                     7 (87.5)      1 (12.5)      
    Presentation of main lesion                                         
      Mass alone                            48 (70.6)     20 (29.4)     \<0.001
      Microcalcifications ± mass            11 (28.9)     27 (71.1)     
      Undetected                            8 (72.7)      3 (27.3)      
    Associated microcalcifications                                      
      Present                               15 (31.2)     33 (68.8)     \<0.001
      Absent                                52 (75.4)     17 (24.6)     
    Shape                                                               
      Round or oval                         38 (63.3)     22 (36.7)     0.252
      Irregular                             15 (57.7)     11 (42.3)     
      Undetected                            14 (45.2)     17 (54.8)     
    Margin                                                              
      Circumscribed                         4 (100.0)     0 (0.0)       0.302[^b^](#t002fn002){ref-type="table-fn"}
      Microlobulated                        7 (58.3)      5 (41.7)      
      Spiculated                            12 (57.1)     9 (42.9)      
      Indistinct                            29 (63.0)     17 (37.0)     
      Obscured                              1 (33.3)      2 (66.7)      
      Undetected                            14 (45.2)     17 (54.8)     
    Density                                                             
      High density                          23 (65.7)     12 (34.3)     0.295
      Equal density                         29 (58.0)     21 (42.0)     
      Low density or undetected             15 (46.9)     17 (53.1)     
  After NCT                                                             
      Complete response or undetected       26 (81.2)     6 (18.8)      0.003[^b^](#t002fn002){ref-type="table-fn"}
      Residual microcalcifications alone    3 (50.0)      3 (50.0)      
      Residual mass ± microcalcifications   38 (48.1)     41 (51.9)     

^a^Independent samples *t*-test.

^b^Fisher's exact test.

[Table 3](#pone.0149347.t003){ref-type="table"} presents the ultrasound results for the ypT0 and ypTis group. Baseline sonographic size, margin, orientation, and echogenicity did not differ between the ypT0 and ypTis group. Round shape of the main lesion, posterior enhancement, and sonographic absence of calcifications were more frequently observed in patients with ypT0. After NCT, ultrasound findings of patients attaining ypT0 showed a higher proportion of complete response.

10.1371/journal.pone.0149347.t003

###### Ultrasound findings of patients with ypT0 and ypTis.

![](pone.0149347.t003){#pone.0149347.t003g}

  Parameters                  ypT0 (%)      ypTis (%)     *P*-value
  --------------------------- ------------- ------------- ---------------------------------------------
  Before NCT                                              
    Mean Size ± SD            29.9 ± 20.0   31.6 ± 18.5   0.641[^a^](#t003fn001){ref-type="table-fn"}
    Shape                                                 
      Oval                    37 (58.7)     26 (41.3)     0.015
      Round                   11 (91.7)     1 (8.3)       
      Irregular               19 (45.2)     23 (54.8)     
    Margin                                                
      Circumscribed           5 (100.0)     0 (0.0)       0.166
      Indistinct              23 (60.5)     15 (39.5)     
      Angular                 9 (69.2)      4 (30.8)      
      Microlobulated          20 (51.3)     19 (48.7)     
      Spiculated              10 (45.5)     12 (54.5)     
    Orientation                                           
      Parallel                38 (50.7)     37 (49.3)     0.054
      Non-parallel            29 (69.0)     13 (31.0)     
    Echogenicity                                          
      Hyper-echo              1 (33.3)      2 (66.7)      0.466[^b^](#t003fn002){ref-type="table-fn"}
      Iso-echo                11 (68.8)     5 (31.2)      
      Hypo-echo               55 (56.1)     43 (43.9)     
    Posterior features                                    
      Enhancement             28 (71.8)     11 (28.2)     0.038
      Shadowing               10 (40.0)     15 (60.0)     
      No posterior features   29 (54.7)     24 (45.3)     
    Calcification                                         
      Present                 9 (28.1)      23 (71.9)     \<0.001
      Absent                  58 (68.2)     27 (31.8)     
  After NCT                                               
      Complete response       27 (75.0)     9 (25.0)      0.010
      Residual disease        40 (49.4)     41 (50.6)     

^a^Independent samples *t*-test.

^b^Fisher's exact test.

MRI findings are shown in [Table 4](#pone.0149347.t004){ref-type="table"}. Before NCT, the size, shape, and margin of the main lesion, background parenchymal enhancement, internal enhancement, T2WI, presence of necrosis, and peritumoral edema did not differ between the two groups. The main lesion of the ypT0 group was more likely to present as a mass, but non-mass enhancement was more frequent in the ypTis group. MRI findings for patients with ypT0 after NCT mostly indicated complete response.

10.1371/journal.pone.0149347.t004

###### Magnetic resonance findings of patients with ypT0 and ypTis.

![](pone.0149347.t004){#pone.0149347.t004g}

  Parameters                      ypT0 (%)      ypTis (%)     *P*-value
  ------------------------------- ------------- ------------- ---------------------------------------------
  Before NCT                                                  
    Mean Size ± SD                30.5 ± 19.9   32.1 ± 17.4   0.656[^a^](#t004fn002){ref-type="table-fn"}
    BPE                                                       
      1                           56 (60.2)     37 (39.8)     0.452[^b^](#t004fn003){ref-type="table-fn"}
      2                           8 (44.4)      10 (55.6)     
      3                           3 (50.0)      3 (50.0)      
    Presentation of main lesion                               
      Mass                        59 (62.1)     36 (37.9)     0.028
      Non-mass enhancement        8 (36.4)      14 (63.6)     
    Shape                                                     
      Round                       14 (60.9)     9 (39.1)      0.282
      Oval                        39 (61.9)     24 (38.1)     
      Irregular                   14 (45.2)     17 (54.8)     
    Margin                                                    
      Circumscribed               13 (65.0)     7 (35.0)      0.403[^b^](#t004fn003){ref-type="table-fn"}
      Irregular                   48 (53.9)     41 (46.1)     
      Spiculated                  6 (75.0)      2 (25.0)      
    Internal enhancement                                      
      Heterogeneous               34 (50.0)     34 (50.0)     0.133
      Homogeneous                 26 (70.3)     11 (29.7)     
      Rim enhancement             7 (58.3)      5 (41.7)      
    Time-intensity curve                                      
      Washout                     64 (95.5)     49 (98.0)     0.830
      Plateau or persistent       3 (4.5)       1 (2.0)       
    T2WI                                                      
      High                        42 (58.3)     30 (41.7)     0.768
      Iso or low                  25 (55.6)     20 (44.4)     
    Presence of necrosis                                      
      No                          58 (56.9)     44 (43.1)     0.819
      Yes                         9 (60.0)      6 (40.0)      
    Peritumoral edema                                         
      No                          48 (57.1)     36 (42.9)     0.966
      Yes                         19 (57.6)     14 (42.4)     
  After NCT                                                   
      Complete response           47 (74.6)     16 (25.4)     \<0.001
      Residual disease            20 (37.0)     34 (63.0)     

BPE, Background parenchymal enhancement; T2WI, T2-weighted image.

^a^Independent samples *t*-test.

^b^Fisher's exact test.

The sensitivity, specificity, and accuracy for the detection of residual DCIS at the time before surgery was 88.0%, 38.8%, and 59.8% for mammography, respectively, 82.0%, 40.3%, and 58.1% for ultrasound, respectively, and 68.0%, 70.1%, and 62.9% for MRI, respectively. [Fig 1](#pone.0149347.g001){ref-type="fig"} shows ROC curve analysis for detecting ypTis. AUC of mammography, ultrasound, and MRI was 0.63 (95% confidence interval \[CI\], 0.53--0.73), 0.61 (95% CI, 0.51--0.71), and 0.69 (95% CI, 0.59--0.79), respectively.

![Receiver operating characteristics (ROC) curve analysis for detecting ypTis.\
AUC, area under the ROC curve; CI, confidence interval; MRI, magnetic resonance imaging.](pone.0149347.g001){#pone.0149347.g001}

Multivariate logistic regression analyses were conducted to identify independent predictors of ypT0 after completion of NCT ([Table 5](#pone.0149347.t005){ref-type="table"}). The triple-negative subtype and complete response in MRI after NCT were significant predictors of ypT0. There was no significant interaction between breast cancer subtypes and MRI results in the multivariate model. Since breast cancer subtypes and MRI findings after NCT were the most important predictors, we conducted stratified analyses according to breast cancer subtype to explore the relationship between MRI findings and residual tumor burden after NCT ([Table 6](#pone.0149347.t006){ref-type="table"}). In all breast cancer subtypes except the HER2-positive subtype, breast MRI well predicted ypT0 with statistical significance. In HRs+/HER2- and HRs+/HER2+ tumors, approximately two-thirds of the patients with complete response observed on MRI after NCT were determined to be ypT0 after surgery, with significant difference. In particular, 22 of 40 patients with HRs-/HER2- tumors showed complete response according to MRI after NCT and among these patients, 21 (95.5%) were ypT0. However, there were no significant differences in patients with HRs-/HER2+ tumors. During the study period, only 2 patients were treated with trastuzumab in combination with chemotherapy since anti-HER2 targeted therapy for neoadjuvant treatment is not covered by the Korean National Health Insurance. When these 2 cases were excluded, MRI findings after NCT were not associated with residual disease in 23 HRs-/HER2+ tumors (*p* = 0.193, Fisher's exact test).

10.1371/journal.pone.0149347.t005

###### Predictors of ypT0 in the breast after completion of NCT.
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  Parameters                            Odds ratio   95% CI        *P*-value
  ------------------------------------- ------------ ------------- -----------
  Breast cancer subtype                                            0.098
      HRs+/HER2-                        Ref                        
      HRs+/HER2+                        0.70         0.16--3.00    0.633
      HRs-/HER2+                        0.97         0.26--3.54    0.958
      HRs-/HER2-                        4.23         1.11--16.09   0.034
  MMG presentation of the main lesion                              
      Mass or undetected                Ref                        
      Microcalcifications ± mass        0.29         0.03--2.51    0.263
  MMG associated microcalcifications                               
      Absent                            Ref                        
      Present                           0.84         0.13--5.60    0.855
  US shape                                                         0.370
      Irregular                         Ref                        
      Oval                              1.11         0.39--3.17    0.846
      Round                             5.83         0.49--69.80   0.164
  US posterior features                                            0.543
      No posterior features             Ref                        
      Shadowing                         1.40         0.38--3.17    0.846
      Enhancement                       1.92         0.60--6.21    0.275
  US calcification                                                 
      No                                Ref                        
      Yes                               1.34         0.22--8.27    0.751
  MRI presentation of the main lesion                              
      Mass                              Ref                        
      Non-mass enhancement              1.18         0.32--4.31    0.807
  MMG after NCT                                                    
      Residual disease                  Ref                        
      Complete response                 0.90         0.20--4.06    0.890
  US after NCT                                                     
      Residual disease                  Ref                        
      Complete response                 2.69         0.79--9.19    0.114
  MRI after NCT                                                    
      Residual disease                  Ref                        
      Complete response                 5.23         1.53--17.85   0.008

CI, confidence interval; Ref, reference; MMG, mammography; US, ultrasound; MRI, magnetic resonance imaging.

10.1371/journal.pone.0149347.t006

###### MRI findings after NCT according to postoperative pathologic results stratified by breast cancer subtype.
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  MRI after NCT           ypT0        ypTis       *P*-value                                     *P*-value[^a^](#t006fn001){ref-type="table-fn"}
  ----------------------- ----------- ----------- --------------------------------------------- -------------------------------------------------
  HRs+/HER2- (n = 33)                                                                           \<0.001
      Complete response   13 (68.4)   6 (31.6)    0.024                                         
      Residual disease    4 (28.6)    10 (71.4)                                                 
  HRs+/HER2+ (n = 19)                                                                           
      Complete response   6 (66.7)    3 (33.3)    0.020[^b^](#t006fn002){ref-type="table-fn"}   
      Residual disease    1 (10.0)    9 (90.0)                                                  
  HRs-/HER2+ (n = 25)                                                                           
      Complete response   7 (53.8)    6 (46.2)    0.226[^b^](#t006fn002){ref-type="table-fn"}   
      Residual disease    3 (25.0)    9 (75.0)                                                  
  HRs-/HER2- (n = 40)                                                                           
      Complete response   21 (95.5)   1 (4.5)     0.033[^b^](#t006fn002){ref-type="table-fn"}   
      Residual disease    12 (66.7)   6 (33.3)                                                  

^a^Cochran-Mantel-Haenszel test.

^b^Fisher's exact test.

Discussion {#sec012}
==========

Recent pooled analyses of clinical trials of NCT indicate that achievement of pCR is associated with improved survival among breast cancer patients \[[@pone.0149347.ref003]\]. However, the implications of these findings are thought to vary among breast cancer subtypes \[[@pone.0149347.ref012]\]. Although several classifications have been suggested for pathologic response to NCT in the breast, pCR of the breast in practice is defined as no residual carcinoma (ypT0) or no residual invasive tumor with DCIS present (ypTis) \[[@pone.0149347.ref013],[@pone.0149347.ref014]\]. The prognostic implications of pCR are somewhat controversial but in general, there are no differences in survival between patients with ypT0 and patients with ypT0/is when ypN0 is attained \[[@pone.0149347.ref003],[@pone.0149347.ref012]\]. However, ypT0 and ypTis cannot be accurately distinguished before definitive surgery, and some tumors do not respond in uniform patterns to NCT \[[@pone.0149347.ref015],[@pone.0149347.ref016]\]. The major clinical advantage of NCT is an increased success rate of breast-conservation surgery, which can be applied to patients with favorable response to NCT who fulfill the criteria for breast-conservation surgery. Therefore, monitoring response to NCT and evaluating residual tumor extent before surgery are clinically important practices.

Mammography is clinically useful for evaluating the extent of malignant-appearing calcifications. Lesions with residual DCIS frequently show calcifications on pre-chemotherapy mammograms \[[@pone.0149347.ref006]\], as observed in this study. When main lesions initially presented as microcalcifications with or without masses or when associated microcalcifications were detected, ypTis was more likely to be observed after NCT. However, calcifications are also indicative of necrotic tumor cells in patients who have received NCT. Our results showed that approximately half of all cases with residual masses or microcalcifications after completion of NCT were identified as ypT0. This result is similar to previous studies which indicated that remnant calcifications after NCT are not correlated with residual tumor burden \[[@pone.0149347.ref006],[@pone.0149347.ref017],[@pone.0149347.ref018]\]. Moreover, 33.3% of stable microcalcifications and 27.7% of newly developed or additional calcifications after NCT turned out to be pCR at the time of surgery, while 100% of calcifications in cases with increased mass showed residual malignancy \[[@pone.0149347.ref019]\]. In HER2-positive breast cancers, adjacent DCIS could be completely eradicated by NCT combined with trastuzumab \[[@pone.0149347.ref020]\]. Therefore, remnant calcifications on mammography after NCT should not be considered to constitute evidence of residual DCIS. While practical guidelines indicate that findings of diffuse suspicious or malignant-appearing microcalcifications absolutely contraindicate breast-conserving therapy \[[@pone.0149347.ref021]\], a comprehensive clinical and imaging analysis which considers breast cancer subtypes and therapeutic regimens is necessary to plan surgery after completion of NCT.

Recently, Lee et al. \[[@pone.0149347.ref022]\] summarized inaccuracies among current practical tools used to evaluate residual tumor volumes in response to NCT and demonstrated that two-dimensional and three-dimensional ultrasound and breast MRI show similar performances for the estimation of residual breast cancer volume and prediction of pCR. In a retrospective analysis of patients enrolled in the GeparTrio trial, ultrasound showed a high sensitivity for predicting ypT0 and ypN0 and modestly improved the prediction of pCR by patient characteristics, which was concluded to be a potentially useful modality for early prediction of pCR, despite breast MRI not being included in the study \[[@pone.0149347.ref023]\]. In addition, ultrasound provides clinical advantages over MRI including lower complexity, easier accessibility, shorter procedure time, easier interpretation, cheaper costs, and lack of the hazards associated with contrast agents \[[@pone.0149347.ref022],[@pone.0149347.ref023]\]. In the present study, univariate analyses demonstrated that round shape on baseline sonographic analyses, posterior features, sonographic absence of calcification, and complete response after NCT were associated with a higher possibility of ypT0. However, there was no significant effect observed in multivariate analysis, and more studies are required to confirm the role of ultrasound in the prediction of residual tumor burden after NCT. Some potential explanations could lie in the fact that all cases included in our study showed pCR at the time of surgery, which means that residual disease was determined by *in situ* components of permanent pathology. No imaging modality other than mammography is currently accepted in the evaluation of DCIS. For example, ultrasound has limited ability to detect microcalcifications due to technical issues \[[@pone.0149347.ref024]\]. Although there are several circumstances in which ultrasound may be beneficial in the evaluation of patients with DCIS, sonographic findings of DCIS are very subtle. Therefore, even though ultrasound might help predict pCR based \[[@pone.0149347.ref023]\], its ability to differentiate ypT0 from ypTis needs to be investigated. In addition, interobserver variability is a well-known limitation of ultrasound \[[@pone.0149347.ref024]\]. Examining the exact primary site can be difficult in cases with markedly decreased tumor burden size due to the limited number of landmarks available for ultrasound.

A meta-analysis of MRI in the prediction of pCR after NCT revealed a high specificity of 0.91 and a relatively low sensitivity of 0.63 \[[@pone.0149347.ref004]\]. However, the performance of MRI can be influenced by pCR rates, Ki-67 index, and breast cancer subtype \[[@pone.0149347.ref004],[@pone.0149347.ref008],[@pone.0149347.ref025],[@pone.0149347.ref026]\]. The accuracy of MRI for predicting residual tumor size was greatest in patients with the triple-negative phenotype or HER2-positive breast cancers, and a better correlation was noted in the triple-negative subtype with higher Ki-67 levels \[[@pone.0149347.ref008],[@pone.0149347.ref025],[@pone.0149347.ref026]\]. In this study, the triple-negative breast cancer subtype and complete response on MRI after NCT were independent predictors for discriminating ypT0 from ypTis. This is supported by previous study results which have shown that mass enhancement is an imaging characteristic of triple-negative breast cancer and that associated DCIS is rare in cases without non-mass enhancement \[[@pone.0149347.ref027]\]. However, Moon et al. \[[@pone.0149347.ref007]\] reported that the use of HER2-targeted agents resulted in less accurate MRI in patients with HER2-positive tumors. In the present study, although most patients with HER2-positive tumors did not receive HER2-directed therapy, MRI after NCT showed poor performance for the prediction of ypT0 in HRs-/HER2+ tumors. Breast cancer subtypes are associated with pCR rates after NCT, and the incorporation of HER2-targeted agents into NCT significantly improved pCR rates in HER2-positive breast cancers \[[@pone.0149347.ref002],[@pone.0149347.ref012],[@pone.0149347.ref028]\]. The relationship between biologic mechanisms and MRI used to discriminate ypT0 from ypTis in HER2-positive tumors has yet to be determined.

Potential limitations of the present study are that it was a retrospective analysis using a single institution database, and that the interpretations of imaging modalities were performed by a single radiologist (although the radiologist was blinded to clinicopathological information). In addition, patients with non-pCR after NCT were not analyzed, and confirmative parameters for the discrimination of ypT0 from ypTis or residual invasive carcinoma were not evaluated. Nevertheless, our study has two major strengths. One is that more than 100 cases attaining pCR in the breast after NCT were investigated and the other is that all patients underwent mammography, ultrasound, and breast MRI prior to and after NCT. Therefore, we were able to comprehensively analyze the impact of all three imaging modalities before and after NCT on the prediction of pCR while considering clinicopathological factors including breast cancer subtype. Our multivariate analyses suggest that MRI after NCT affects discrimination between ypT0 and ypTis differently according to breast tumor phenotype. Of note, since the high false-positive rate and the subsequently frequent overcall rate are weaknesses of MRI, further study with a larger multicenter cohort is necessary to validate our results and to evaluate the clinical benefits and risks of MRI.

In conclusion, we demonstrated that the triple-negative breast cancer subtype and complete response in MRI after NCT are independent predictors of ypT0. Among imaging modalities, breast MRI could be suggested as a modality that accurately discriminates between ypT0 and ypTis after NCT, especially in patients with triple-negative breast cancer. However, statistically low AUC value and relatively high false-positive rate of MRI given in the present study suggest that our findings are not definitive and additional study should be conducted. Until finding out more clinically relevant imaging modalities and appropriate patient selection criteria, this information can be useful in the evaluation of tumor response to NCT and in the planning of surgery for breast cancer patients of all subtypes except for HER2-positive tumors after NCT.

Supporting Information {#sec013}
======================

###### The raw data of image review.

(PDF)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: SP MJK. Performed the experiments: MJK. Analyzed the data: SP MJK. Contributed reagents/materials/analysis tools: SP JHY JS HSP HJM MJK EKK SIK BWP. Wrote the paper: SP MJK. Proofread or rechecked the manuscript: SP JHY JS HSP HJM MJK EKK SIK BWP.
